Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: too early to draw conclusions

EuroIntervention 2018;14:e487-e489 published online e-edition August 2018. DOI: 10.4244/EIJV14I5A85

Jacob Lønborg
Jacob Lønborg, MD, PhD, DMSc; Thomas Engstrøm, MD, PhD, DMSc; Ole De Backer, MD, PhD; Lars Søndergaard*, MD, DMSc
Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Severe aortic stenosis (AS) is frequently present in the ageing population and is related to mortality and morbidity. Traditionally, this disease has been treated with surgical aortic valve replacement (SAVR); however, during the last decade the field has been revolutionised by the less invasive transcatheter aortic valve implantation (TAVI). The number of TAVI procedures is increasing rapidly and, as the boundaries of TAVI are continuously pushed, there is an increased need for knowledge on how to deal with comorbidities.

Concomitant coronary artery disease (CAD) is a frequent comorbidity observed in up to 50% of patients selected for TAVI1. The ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Sizing for self-expanding transcatheter aortic valve implantation

Latest news